CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be holding a symposium at the 84th American Association for Neurological Surgeons (AANS) Annual Scientific Meeting on Monday, May 2, 2016 in Chicago, IL. InVivo will have several other engagement opportunities, including a Steering Committee meeting and an exhibitor booth.
The symposium presentation is titled “Innovation in Spinal Cord Injury Treatment: The Investigational Neuro-Spinal Scaffold™ and Bioengineered Neural Trails™” and will feature presentations by three renowned key opinion leaders: Robert Langer, Sc.D., the David H. Koch Institute Professor at Massachusetts Institute of Technology and co-founder of InVivo; Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center and neurosurgeon for three Neuro-Spinal Scaffold™ implantations; and James Guest, M.D., Ph.D., Professor of Clinical Neurosurgery at the University of Miami’s Miller School of Medicine and inventor on the novel cell delivery patent InVivo recently acquired.
“We remain committed to broadening our outreach within the neurosurgical community. Our previous symposium at the Spine Summit proved to be productive in strengthening our current relationships and fostering new ones. With over 3,000 attendees expected at the AANS meeting, our second symposium will continue to build and expand our reach in the neurosurgical community,” Mark Perrin, InVivo’s CEO and Chairman, said.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.